A 50 by 7 data matrix of a contingency table processed from the FDA Adverse Event Reporting System (FAERS) database from Q3 2014 to Q4 2020.
Details
A 50 by 7 data matrix of a contingency table from the FDA Adverse Event Reporting System (FAERS) database, covering Q3 2014 to Q4 2020.
The 49 rows represent important adverse events associated with statins,
with the final row aggregating the remaining 5,990 events. The 49 AEs are
classified into three clusters (see statin49_AE_idx
for cluster indices):
1) AEs associated with muscle injury signs and symptoms, 2) AEs associated with muscle injury lab tests, and 3) AEs associated with kidney injury and its diagnosis and treatment.
The 7 columns include six statin medications and an "other drugs" column. Marginal totals for each drug: 197,390 for Atorvastatin, 5,742 for Fluvastatin, 3,230 for Lovastatin, 22,486 for Pravastatin, 122,450 for Rosuvastatin, 85,445 for Simvastatin, and 63,539,867 for Other drugs.
Examples
data(statin49)
head(statin49)
#> Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin
#> Rhabdomyolysis 2041 52 44 163 936
#> Muscle Disorder 291 2 7 21 191
#> Muscle Fatigue 85 0 2 16 30
#> Muscle Haemorrhage 24 0 0 5 13
#> Muscle Necrosis 68 2 0 1 10
#> Muscle Rupture 181 25 0 61 36
#> Simvastatin Other
#> Rhabdomyolysis 1376 31707
#> Muscle Disorder 87 7329
#> Muscle Fatigue 39 4257
#> Muscle Haemorrhage 4 3806
#> Muscle Necrosis 20 662
#> Muscle Rupture 120 3219